Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors
International Journal of Molecular Sciences · 13.06.2023 · 24 (12) · 10082
DOI: 10.3390/ijms241210082 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.06.2023. Verfasst von Jinseong Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Woman's University, Seoul 03760, Republic of Korea. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 127-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Over the past few decades, the enhanced permeability and retention (EPR) effect of nanomedicine has been a crucial phenomenon in targeted cancer therapy. Specifically, understanding the EPR effect has been a significant aspect of delivering anticancer agents efficiently to targeted tumors. Although the therapeutic effect has been demonstrated in experimental models using mouse xenografts, the clinical translation of the EPR effect of nanomedicine faces several challenges due to dense extracellular matrix (ECM), high interstitial fluid pressure (IFP) levels, and other factors that arise from tumor heterogeneity and complexity. Therefore, understanding the mechanism of the EPR effect of nanomedicine in clinics is essential to overcome the hurdles of the clinical translation of nanomedicine. This paper introduces the basic mechanism of the EPR effect of nanomedicine, the recently discussed challenges of the EPR effect of nanomedicine, and various strategies of recent nanomedicine to overcome the limitations expected from the patients’ tumor microenvironments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Woman's University, Seoul 03760, Republic of Korea.
- KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea.
- Noxpharm Co., Ltd., #518, 150, Bugahyeon-ro, Seodaemun-gu, Seoul 03759, Republic of Korea.
ORCID-Profile: Kwangmeyung Kim
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, J., Cho, H., Lim, D. K., Joo, M. K., & Kim, K. (2023). Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors. International Journal of Molecular Sciences, 24(12), 10082. https://doi.org/10.3390/ijms241210082
Vancouver
Kim J, Cho H, Lim DK, Joo MK, Kim K. Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors. International Journal of Molecular Sciences. 2023;24(12):10082. doi:10.3390/ijms241210082
BibTeX
@article{Kim2023,
author = {Kim, Jinseong and Cho, Hanhee and Lim, Dong-Kwon and Joo, Min Kyung and Kim, Kwangmeyung},
title = {Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {12},
pages = {10082},
doi = {10.3390/ijms241210082}
}
EUVIMED